FcRn blockers are being developed as a potential treatment for Sjogren's disease, with the goal of becoming the first approved drug for the condition. Some of these blockers, such as nipocalimab and efgartigimod, have already shown therapeutic benefits in other autoimmune diseases, including myasthenia gravis. The development and comparison of these blockers are ongoing, with studies and trials assessing their efficacy in various conditions.